10. Microvascular Complications and Foot Care

doi:10.2337/dc17-s013

journal article Dec 12, 2016

10. Microvascular Complications and Foot Care

Diabetes Care Vol. 40 No. Supplement_1 pp. S88-S98 · American Diabetes Association

View at Publisher Save 10.2337/dc17-s013

Topics

No keywords indexed for this article. Browse by subject →

References

109

[1]

Tuttle "Diabetic kidney disease: a report from an ADA Consensus Conference" Diabetes Care (2014) 10.2337/dc14-1296

[2]

National Kidney Foundation "KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease" Kidney Int Suppl (2013)

[3]

Delanaye "An age-calibrated definition of chronic kidney disease: rationale and benefits" Clin Biochem Rev (2016)

[4]

National Kidney Foundation Practice Guidelines for Chronic Kidney Disease: Evaluation, Classification, and Stratification

Andrew S. Levey, Josef Coresh, Ethan Balk et al.

Annals of Internal Medicine 2003 10.7326/0003-4819-139-2-200307150-00013

[5]

de Boer "Temporal trends in the prevalence of diabetic kidney disease in the United States" JAMA (2011) 10.1001/jama.2011.861

[6]

Afkarian "Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014" JAMA (2016) 10.1001/jama.2016.10924

[7]

Kramer "Renal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus" JAMA (2003) 10.1001/jama.289.24.3273

[8]

Molitch "Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the Diabetes Control and Complications Trial and the Epidemiology of Diabetes Interventions and Complications study" Diabetes Care (2010) 10.2337/dc09-1098

[9]

He "Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis" Diabetologia (2013) 10.1007/s00125-012-2796-6

[10]

Boer "Albuminuria changes and cardiovascular and renal outcomes in type 1 diabetes: the DCCT/EDIC study" Clin J Am Soc Nephrol (2016) 10.2215/cjn.02870316

[11]

DCCT/EDIC Research Group "Effect of intensive diabetes treatment on albuminuria in type 1 diabetes: long-term follow-up of the Diabetes Control and Complications Trial and Epidemiology of Diabetes Interventions and Complications study" Lancet Diabetes Endocrinol (2014) 10.1016/s2213-8587(14)70155-x

[12]

Intensive Diabetes Therapy and Glomerular Filtration Rate in Type 1 Diabetes

New England Journal of Medicine 2011 10.1056/nejmoa1111732

[13]

UK Prospective Diabetes Study (UKPDS) Group "Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)" Lancet (1998) 10.1016/s0140-6736(98)07037-8

[14]

UK Prospective Diabetes Study (UKPDS) Group "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)" Lancet (1998) 10.1016/s0140-6736(98)07019-6

[15]

Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 Diabetes

New England Journal of Medicine 2008 10.1056/nejmoa0802987

[16]

Ismail-Beigi "Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial" Lancet (2010) 10.1016/s0140-6736(10)60576-4

[17]

Zoungas "Follow-up of blood-pressure lowering and glucose control in type 2 diabetes" N Engl J Med (2014) 10.1056/nejmoa1407963

[18]

Renal Hemodynamic Effect of Sodium-Glucose Cotransporter 2 Inhibition in Patients With Type 1 Diabetes Mellitus

David Z.I. Cherney, Bruce A. Perkins, Nima Soleymanlou et al.

Circulation 2014 10.1161/circulationaha.113.005081

[19]

Wanner "Empagliflozin and progression of kidney disease in type 2 diabetes" N Engl J Med (2016) 10.1056/nejmoa1515920

[20]

Heerspink "Canagliflozin slows progression of renal function decline independently of glycemic effects" J Am Soc Nephrol. (2016)

[21]

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes

Steven P. Marso, Gilbert H. Daniels, Kirstine Brown-Frandsen et al.

New England Journal of Medicine 2016 10.1056/nejmoa1603827

[22]

Cooper "Kidney disease end points in a pooled analysis of individual patient-level data from a large clinical trials program of the dipeptidyl peptidase 4 inhibitor linagliptin in type 2 diabetes" Am J Kidney Dis (2015) 10.1053/j.ajkd.2015.03.024

[23]

Miller "The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study" BMJ (2010) 10.1136/bmj.b5444

[24]

Papademetriou "Chronic kidney disease and intensive glycemic control increase cardiovascular risk in patients with type 2 diabetes" Kidney Int (2015) 10.1038/ki.2014.296

[25]

Perkovic "Intensive glucose control improves kidney outcomes in patients with type 2 diabetes" Kidney Int (2013) 10.1038/ki.2012.401

[26]

Wong "Long-term benefits of intensive glucose control for preventing end-stage kidney disease: ADVANCE-ON" Diabetes Care (2016) 10.2337/dc15-2322

[27]

KDOQI Clinical Practice Guideline for Diabetes and CKD: 2012 Update

American Journal of Kidney Diseases 2012 10.1053/j.ajkd.2012.07.005

[28]

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

Bernard Zinman, Christoph Wanner, John M. Lachin et al.

New England Journal of Medicine 2015 10.1056/nejmoa1504720

[29]

U.S. Department of Health and Human Services. U.S. Food and Drug Administration: FDA drug safety communication: FDA revises warnings regarding use of the diabetes medicine metformin in certain patients with reduced kidney function [Internet]. Available from http://www.fda.gov/Drugs/DrugSafety/ucm493244.htm. Accessed 15 October 2016

[30]

Emdin "Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis" JAMA (2015) 10.1001/jama.2014.18574

[31]

ACCORD Study Group "Effects of intensive blood-pressure control in type 2 diabetes mellitus" N Engl J Med (2010) 10.1056/nejmoa1001286

[32]

UK Prospective Diabetes Study Group "Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38" BMJ (1998) 10.1136/bmj.317.7160.703

[33]

Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy

Barry M. Brenner, Mark E. Cooper, Dick de Zeeuw et al.

New England Journal of Medicine 2001 10.1056/nejmoa011161

[34]

Lewis "The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy" N Engl J Med (1993) 10.1056/nejm199311113292004

[35]

Lewis "Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes" N Engl J Med (2001) 10.1056/nejmoa011303

[36]

National Kidney Foundation "KDIGO clinical practice guideline for the management of blood pressure in chronic kidney disease" Kidney Int Suppl (2012)

[37]

Heart Outcomes Prevention Evaluation Study Investigators "Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy" Lancet (2000) 10.1016/s0140-6736(99)12323-7

[38]

Barnett "Angiotensin-receptor blockade versus converting-enzyme inhibition in type 2 diabetes and nephropathy" N Engl J Med (2004) 10.1056/nejmoa042274

[39]

Parving "The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes" N Engl J Med (2001) 10.1056/nejmoa011489

[40]

Bangalore "Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials" BMJ (2016) 10.1136/bmj.i438

[41]

Haller "Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes" N Engl J Med (2011) 10.1056/nejmoa1007994

[42]

Mauer "Renal and retinal effects of enalapril and losartan in type 1 diabetes" N Engl J Med (2009) 10.1056/nejmoa0808400

[43]

ONTARGET Investigators "Telmisartan, ramipril, or both in patients at high risk for vascular events" N Engl J Med (2008) 10.1056/nejmoa0801317

[44]

Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy

George L. Bakris, Rajiv Agarwal, Juliana C. Chan et al.

JAMA 2015 10.1001/jama.2015.10081

[45]

Williams "Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial" Lancet (2015) 10.1016/s0140-6736(15)00257-3

[46]

A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease

Gerasimos Filippatos, Stefan D. Anker, Michael Böhm et al.

European Heart Journal 2016 10.1093/eurheartj/ehw132

[47]

Berl "Cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial of patients with type 2 diabetes and overt nephropathy" Ann Intern Med (2003) 10.7326/0003-4819-138-7-200304010-00010

[48]

Smart "Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease" Cochrane Database Syst Rev (2014)

[49]

Klein "Hyperglycemie and microvascular and macrovascular disease in diabetes" Diabetes Care (1995) 10.2337/diacare.18.2.258

[50]

Estacio "Overt albuminuria predicts diabetic retinopathy in Hispanics with NIDDM" Am J Kidney Dis (1998) 10.1053/ajkd.1998.v31.pm9631838

Showing 50 of 109 references

Metrics

114

Citations

109

References

Details

Published: Dec 12, 2016
Vol/Issue: 40(Supplement_1)
Pages: S88-S98
License: View

Cite This Article

(2016). 10. Microvascular Complications and Foot Care. Diabetes Care, 40(Supplement_1), S88-S98. https://doi.org/10.2337/dc17-s013

10. Microvascular Complications and Foot Care

You May Also Like